HyperGam+CF data

NIIUF and NABI announced that they stopped a Phase II trial after an interim analysis showed no reduction in the number of acute pulmonary exacerbations.

The analysis included data from 175 CF patients who were colonized with mucoid Pseudomonas and who had a history of infections requiring hospitalization. Of these, 116 had completed at least six months of treatment. Data from the placebo-controlled, double blind, dose-ranging trial showed no trends toward a difference in efficacy between treated patients receiving either a high or low dose of HyperGam, or placebo. ...